Skip to main content
. Author manuscript; available in PMC: 2019 Apr 15.
Published in final edited form as: Immunopharmacol Immunotoxicol. 2014 Feb 5;36(2):182–186. doi: 10.3109/08923973.2013.864671

Table 1:

Summary of Patients

Patient Sex Age NSCLC Histology Prior Lines of Treatment Best Response to TLF PFS (weeks)
1001 F 50 Adenocarcinoma 5 PR 34
1002 M 52 Adenosquamous 2 SD 24
1003 M 62 Adenocarcinoma 3 PD 7
1004 F 75 Adenocarcinoma 2 PD 7